Early phase CGT trials: key design elements for biological characteristics

With increasing numbers of cell and gene therapies (CGTs) entering clinical trials, Dr Dave Li and Dr Anna Baran of KCR Consulting discuss how the biological characteristics of CGTs should be taken into account with early phase trial designs.

Related Keywords

United States ,Washington ,London ,City Of ,United Kingdom ,Anna Baran ,Dave Li ,Johns Hopkins ,Clinical Development Of Gene Therapies ,Drug Administration ,Investigational New Drug Development Of Cell ,Md Anderson Cancer Center ,Takeda Pharmaceuticals ,Committee For Advanced Therapies ,European Union ,European Medicines Agency ,National Academies ,National Academies Of Sciences ,National Comprehensive Cancer Network ,Principal Consultant ,Trial Execution Consulting ,Cancer Center ,Chief Medical Officer ,Trial Execution ,Gene Therapies ,First Three Decades ,Mol Ther Methods Clin ,Ther Methods Clin ,Early Phase Clinical Trials ,Gene Therapy Products Guidance ,Gene Therapy ,Rare Diseases Guidance ,Medicines Agency ,Advanced Therapies ,Human Cell Based Medicinal ,Novel Clinical Trial Designs ,Gene Based Therapies ,Curr Stem Cell ,Clinical Trials Supporting ,Marketing Authorisation ,Rare Dis Res ,Term Follow Up After Administration ,Human Gene Therapy Products Guidance ,